Talk:Reata Pharmaceuticals

This article is rated Start-class on Wikipedia's content assessment scale.
It is of interest to the following WikiProjects:

Companies Mid‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles

Mid This article has been rated as Mid-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

It is herein proposed that the topic of limiting the study to Type 2 Diabetes be explained and discussed. Additions from anyone having direct knowledge of this facet of the study involving the effects of bardoxolone methyl on renal disease would be appreciated. It would also be interesting to know if any other country is currently prescribing it for use in the treatment of real disease, and, if so, what their results have been.FriendMR (talk) 02:45, 7 October 2011 (UTC)[reply]